Skip to main content
. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318

Figure 1. Overview of patient cohorts and analyses included in the study.

Figure 1

(A) In a prospective trial to identify biomarker candidates for nivolumab treatment (Nivolution trial), a total 50 patients with advanced or recurrent NSCLC previously treated with any systemic therapy (cohort A) was analyzed. (B) Retrospective analysis of 149 patients with advanced or recurrent NSCLC who received monotherapy with any PD-1 or PD-L1 inhibitor in the first- or later-line setting (cohort B). Flow cytometry (FCM) and microarray analysis of gene expression were performed for peripheral CD8+ T cells from 56 and 40 patients, respectively, enrolled at Kyoto University Hospital, which was previously reported (27) (C) Retrospective analysis of patients who underwent more than 1 line of systemic therapy before ICI treatment at Kyoto University Hospital (cohort C) (27) (D and E) Retrospective analysis of 42 and 43 patients with advanced or recurrent NSCLC who received cytotoxic chemotherapy (cohort D) or targeted therapy (cohort E) in the first-line setting, respectively.